Speakers 2012
ABD EL-FATTAH Sherif
Egypt
-
How to optimize treatment of G1 patient ?
Presentation
-
-
How to optimize treatment of G4 patients (chairman)
-
Controversies Part 1 (chairman)
Presentation
-
AGHEMO Alessio
Italy
-
How to optimize treatment of G2 and G3 patients
Presentation
-
ALBERTI Alfredo
Italy
-
What’s new in non G1 ? (chairman)
-
How to manage non responders and relapsers ? (chairman)
Presentation
-
ANTAKI Nabil
Syria
-
How to optimize treatment of G4 patients
Presentation
-
-
Future therapies (chairman)
-
State of the Art Lecture (chairman)
-
State of the Art Lecture (chairman)
-
Advantages of new generation DAAs
Presentation
-
BACON Bruce
USA
-
Boceprevir
Presentation
-
BARTENSCHLAGER Ralf
Germany
-
New targets for antivirals against HCV
-
Future therapies
Presentation
-
-
Non invasive markers of fibrosis (chairman)
Presentation
-
BELHADJ BRIK Najet
Tunisia
-
French speaking luncheon : Comment optimiser le traitement des patients naifs
Presentation
-
-
French speaking luncheon : Comment optimiser la prise en charge des patients rechuteurs et non répondeurs
Presentation
-
BERENGUER Marina
Spain
-
How to optimize treatment of G1 patient ? (chairman)
Presentation
-
-
Cirrhotics
Presentation
-
-
How to manage G1 relapsers and non responders ?
Presentation
-
-
How to manage non responders and relapsers ?
Presentation
-
CALES Paul
France
-
Non invasive markers of fibrosis
Presentation
-
CARDOSO Ana Carolina
Brazil
-
Non invasive markers of fibrosis
Presentation
-
-
Treatment of patients with cirrhosis
Presentation
-
-
Triple therapy today. Phase III results in G1 naïve patients (chairman)
-
How to optimize treatment of non G1 patient ? (chairman)
Presentation
-
COUZIGOU Patrice
France
-
French speaking luncheon : Comment optimiser le traitement des patients naifs (chairman)
Presentation
-
-
The EASL HCV Clinical Practice Guidelines
-
How to optimize treatment of G1 patient ? (chairman)
Presentation
-
-
Non invasive markers of fibrosis
Presentation
-
DUSHEIKO Geoffrey
UK
-
Triple therapy today. Phase III results in G1 relapsers and non responders (chairman)
Presentation
-
-
Genotype 4
Presentation
-
-
Are interferons really necessary ?
Presentation
-
FLISIAK Robert
Poland
-
Future therapies
Presentation
-
-
How to optimize treatment of G2 and G3 patients (chairman)
-
How to optimize treatment of G2 and G3 patients
-
Genotype 3
-
Lead in or no lead in ?
Presentation
-
-
How to optimize treatment of G1 patients (chairman)
-
How to improve access to therapy
Presentation
-
-
Resistance is important : Yes or No ?
Presentation
-
-
Safety management in clinical practicee
Presentation
-
HOOFNAGLE Jay
USA
-
The history of HCV therapy
Presentation
-
HORBAN Andrzej
Poland
-
How to optimize treatment of G1 patient ?
Presentation
-
-
Telaprevir
Presentation
-
-
How to manage sides effects of triple therapy ? (chairman)
-
Do IL28B or not do IL28B ?
Presentation
-
-
The future (chairman)
Presentation
-
-
What’s new in non G1 ? (chairman)
Presentation
-
KWO Paul
USA
-
Clinical relevance of predictors
Presentation
-
-
How to avoid a resistance issue ?
Presentation
-
-
How to optimize treatment of G1 patients
Presentation
-
-
How to manage sides effects of triple therapy ?
-
Special Populations (chairman)
Presentation
-
LEROY Vincent
France
-
How to manage sides effects of triple therapy ?
Presentation
-
-
Future therapies
Presentation
-
-
The future (chairman)
Presentation
-
-
Genotype 2
-
How to optimize treatment of non G1 patient ?
Presentation
-
MANNS Michael
Germany
-
Triple therapy today. Phase III results in G1 naïve patients (chairman)
-
Boceprevir
-
How to manage G1 relapsers and non responders ? (chairman)
Presentation
-
-
Introduction : Hepatitis C : A big step towards eradication
-
State of the Art Lecture (chairman)
-
State of the Art Lecture (chairman)
-
Introduction
-
Introduction
-
Conclusion and perspectives
Presentation
-
MATHURIN Philippe
France
-
How to optimize treatment of G4 patients
Presentation
-
MOUCARI Rami
United Arab Emirates
-
How to optimize treatment of non G1 patient ?
Presentation
-
-
Future therapies
Presentation
-
-
Future therapies (chairman)
-
Is Ribavirin still useful ?
Presentation
-
-
Controversies Part 2 (chairman)
Presentation
-
OULD GOUGAM Rachid
Algeria
-
French speaking luncheon : Comment optimiser le traitement des patients naifs
Presentation
-
-
French speaking luncheon : Comment optimiser le traitement des patients naifs
Presentation
-
-
How to manage G1 relapsers and non responders ?
Presentation
-
-
Special Populations (chairman)
Presentation
-
-
Do IL28B or not do IL28B ?
Presentation
-
RATZIU Vlad
France
-
How to manage sides effects of triple therapy ?
Presentation
-
REDDY Raj
USA
-
Response unguided or guided ?
Presentation
-
-
Pre and post liver transplantation
Presentation
-
SARRAZIN Christoph
Germany
-
Resistance is important : Yes or No ?
Presentation
-
-
Triple therapy today. Phase III results in G1 relapsers and non responders (chairman)
-
How to manage sides effects of triple therapy ? (chairman)
Presentation
-
-
Introduction : Is the game over ?
Presentation
-
SERFATY Lawrence
France
-
Lead in or no lead in ?
-
How to manage non responders and relapsers ?
Presentation
-
-
Telaprevir or Boceprevir ?
-
How to avoid a resistance issue ? (chairman)
Presentation
-
-
Future therapies
-
HCV-HIV coinfection
Presentation
-
THURSZ Mark
UK
-
Controversies Part 2 (chairman)
-
Treatment of patients with cirrhosis
Presentation
-
TRAN Albert
France
-
French speaking luncheon : Comment optimiser la prise en charge des patients rechuteurs et non répondeurs
Presentation
-
-
French speaking luncheon : Comment optimiser la prise en charge des patients rechuteurs et non répondeurs (chairman)
Presentation
-
VALLA Dominique
France
-
Treatment of patients with cirrhosis (chairman)
Presentation
-
-
French speaking luncheon : Comment optimiser la prise en charge des patients rechuteurs et non répondeurs
Presentation
-
-
How to optimize treatment of G4 patients
Presentation
-
WEILAND Ola
Sweden
-
How to manage sides effects of triple therapy ?
Presentation
-
YURDAYDIN Cihan
Turkey
-
How to optimize treatment of G1 patients
Presentation
-
-
Controversies Part 1 (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
Telaprevir
Presentation
-
ZOULIM Fabien
France
-
Response unguided or guided ?
-
How to avoid a resistance issue ?
Presentation
-
